CFO Pathways Report 2023

Despite the economic headwinds of inflation, restricted funding, and the resulting private equity inertia, the global CFO market remains exceptionally buoyant. In this report Criticaleye Partner Eton Bridge shares their research on the international analysis of Chief Financial Officer appointments in 2023.
 
Key Takeaways:

  • Private Equity (PE) continues to dominate global hiring markets, and a lack of PE experience can be considered a major hindrance to a CFO’s career progression.
  • Gender disparity remains entrenched but continues to be an important consideration in the majority of appointment processes.
  • Both aspiring and experienced CFOs will remain in high demand into 2024.




Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Click here to download this insight
Responsible AI at Eightfold

Artificial Intelligence, a force with the potential to revolutionise various aspects of people's lives and business operations, demands responsible and ethical decision-making. This is particularly crucial in HR. Cr...

Click here to download this insight
HR Director Research Results ...

This research, conducted at our HR Director Retreat, highlights the executive focus on business performance and ensuring the right leadership capabilities are in place to drive change and success. Key findings from C...

Click here to download this insight
Steering Change at Rolls-Royc...

Sarah Armstrong, Chief People Officer at Rolls-Royce, talks to Senior Editor Bridgette Hall at Criticaleye about guiding the company’s workforce through transformation, focusing on skills and capabilities and her ...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 1,517




Lightsource bp Eightfold AI London Stock Exchange Accenture Google AlixPartners Legal & General Investment Management Robert Walters Drax Group plc Workday Concentrix Eton Bridge Partners Amazon UK Veolia Water Technologies Royal London Group Redwood Bank Tullow Oil plc NATS Mayborn Group LDC Salesforce Bunzl plc GlaxoSmithKline plc E.ON UK